Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Diamedica Therapeutics ( (DMAC) ) has issued an announcement.
On December 19, 2025, DiaMedica Therapeutics Inc. sold 1,501,000 common shares to a healthcare institutional fund at a price of $8.10 per share in a block transaction conducted under its at-the-market offering program, generating $12.2 million in gross proceeds before fees and expenses. The capital raise strengthens the company’s financial position and provides additional funding flexibility for its ongoing operations and development activities, potentially supporting its strategic initiatives in the biopharmaceutical market.
The most recent analyst rating on (DMAC) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Diamedica Therapeutics stock, see the DMAC Stock Forecast page.
Spark’s Take on DMAC Stock
According to Spark, TipRanks’ AI Analyst, DMAC is a Neutral.
The score is held down primarily by pre-revenue financial performance with widening losses and accelerating cash burn, despite a clean, low-debt balance sheet. Offsetting factors include a mixed-to-positive earnings update (encouraging preeclampsia data and strong cash position) and moderately supportive longer-term technical trends, while valuation is less supportive due to negative earnings and no dividend.
To see Spark’s full report on DMAC stock, click here.
More about Diamedica Therapeutics
DiaMedica Therapeutics Inc. is a biopharmaceutical company focused on developing therapeutic products, particularly within the healthcare sector, targeting unmet medical needs through innovative treatments.
Average Trading Volume: 404,532
Technical Sentiment Signal: Strong Buy
Current Market Cap: $413M
See more data about DMAC stock on TipRanks’ Stock Analysis page.